Procter & Gamble (P&G) has this week terminated an
agreement with Nastech to develop a nasally delivered version of
Eli Lilly's osteoporosis drug Forteo (teriparatide), leaving its
partner with no explanation for the...
Swiss firm Novartis has gained US approval of its once-yearly
treatment for postmenopausal osteoporosis, with EU approval
expected to follow hot on its heels.
Nastech has secured a contract with Procter & Gamble (P&G)
to ramp up manufacturing capacity for a new needle-free drug to
beat osteoporosis, in anticipation of meeting expected global
demand once the product is approved.
Biotechnology firm Nastech has chosen Procter & Gamble to
develop and commercialise its osteoporosis nasal spray worldwide,
in a lucrative deal that could reach $577m (€480m) over the life of
the project and give both companies...
Galapagos Genomics are set to receive additional milestone payments
of up to $40 million (€30.9 million) after its osteoporosis
discovery program with Wyeth Pharmaceuticals resulted in the US
drug gaints successfully selecting novel...
Unigene, which specialises in developing oral versions of
injectable drugs, has received a $4 million (€3.3m) milestone
payment from pharmaceutical major GlaxoSmithKline for starting
clinical trials of an osteoporosis drug.
A new patch product in clinical trials could provide a
patient-friendly means of delivering the only drug treatment for
osteoporosis that can actually replace lost bone, reports Phil
Taylor.
Osteoporosis sufferers are set to benefit from an influx of new
drug treatments which are expected to dominate the market and give
patients an unprecedented choice of treatment options, according to
new market research which suggetss...